MiRagen Therapeutics announces Joshua Resnick to its Board after raising $41m Series C financing co-led by MRL Ventures and JAFCO
– USA, CO – miRagen Therapeutics, a biopharmaceutical company developing innovative microRNA-based therapeutics, today announced a Series C Preferred Stock financing with gross proceeds of $41 million, including conversion of outstanding notes.…